%0 Figure %A Cohen-Barak, Orit %A Weiss, Sivan %A Rasamoelisolo, Michele %A Faulhaber, Nicola %A Yeung, Paul P %A Loupe, Pippa S %A Yoon, Esther %A Gandhi, Mohit D %A Spiegelstein, Ofer %A Aycardi, Ernesto %D 2018 %T Supplementary Figure 1 middle panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects %U https://sage.figshare.com/articles/figure/Supplementary_Figure_1_middle_panel_-Supplemental_material_for_A_phase_1_study_to_assess_the_pharmacokinetics_safety_and_tolerability_of_fremanezumab_doses_225_mg_675_mg_and_900_mg_in_Japanese_and_Caucasian_healthy_subjects/6159611 %R 10.25384/SAGE.6159611.v1 %2 https://sage.figshare.com/ndownloader/files/11138009 %K Calcitonin-gene-related peptide %K CGRP %K fremanezumab %K preventive migraine treatments %K TEV-48125 %X

Supplemental material, Supplementary Figure 1 middle panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia

%I SAGE Journals